Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery (original) (raw)

References

  1. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56–65.
    Article Google Scholar
  2. Odstrcil EA, Martinez JG, Santa Ana CA, Xue B, Schneider RE, Steffer KJ et al. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr 2010; 92: 704–713.
    Article CAS Google Scholar
  3. Werling M, Fändriks L, Olbers T, Bueter M, Sjöström L, Lönroth H et al. Roux-en-Y gastric bypass surgery increases respiratory quotient and energy expenditure during food intake. PLoS One 2015; 10: e0129784.
    Article Google Scholar
  4. Schmidt JB, Pedersen SD, Gregersen NT, Vestergaard L, Nielsen MS, Ritz C et al. Effects of RYGB on energy expenditure, appetite and glycemic control: a randomized controlled clinical trial. Int J Obes (Lond) 2016; 40: 281–290.
    Article CAS Google Scholar
  5. Dirksen C, Damgaard M, Bojsen-Møller KN, Jørgensen NB, Kielgast U, Jacobsen SH et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone reponses after Roux-en-Y gastric bypass. Neurogastroenterol Motil 2013; 25: 346–e255.
    Article CAS Google Scholar
  6. Madsbad S, Dirksen C, Holst JJ . Mechanisms of changes in glucose metabolism and body weight after bariatric surgery. Lancet Diabetes Endocrinol 2014; 2: 152–164.
    Article CAS Google Scholar
  7. Bojsen-Møller KN, Dirksen C, Jørgensen NB, Jacobsen SH, Serup AK, Albers PH et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 2014; 63: 1725–1737.
    Article Google Scholar
  8. Jørgensen NB, Jacobsen SH, Dirksen C, Bojsen-Møller KN, Naver L, Hvolris L et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 2012; 303: E122–E131.
    Article Google Scholar
  9. Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012; 22: 1084–1096.
    Article CAS Google Scholar
  10. Wewer Albrechtsen NJ, Hornburg D, Albrechtsen R, Svendsen B, Toräng S, Jepsen SL et al. Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. EBioMedicine 2016; 7: 112–120.
    Article Google Scholar
  11. Le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780–785.
    Article Google Scholar
  12. De Hollanda A, Casals G, Delgado S, Jiménez A, Viaplana J, Lacy AM et al. Gastrointestinal hormones and weight loss maintenance following Roux-en-Y Gastric Bypass. J Clin Endocrinol Metab 2015; 100: 4677–4684.
    Article CAS Google Scholar
  13. Harris AG . Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994; 35: S1–S4.
    Article CAS Google Scholar
  14. Batterham RL, Cowley Ma, Small CJ, Herzog H, Cohen Ma, Dakin CL et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650–654.
    Article CAS Google Scholar
  15. De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA et al. The gut hormones PYY 3–36 and GLP-1 7–36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011; 14: 700–706.
    Article CAS Google Scholar
  16. Verdic C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM et al. A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382–4389.
    Google Scholar
  17. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120–5127.
    Article CAS Google Scholar
  18. Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW et al. Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab 2014; 306: E1248–E1256.
    Article CAS Google Scholar
  19. Keire DA, Mannon P, Kobayashi M, Walsh JH, Solomon TE, Reeve JR . Primary structures of PYY, [Pro(34)]PYY, and PYY-(3–36) confer different conformations and receptor selectivity. Am J Physiol Gastrointest Liver Physiol 2000; 279: G126–G131.
    Article CAS Google Scholar
  20. Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, Hansen DL et al. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013; 62: 3044–3052.
    Article Google Scholar
  21. Svane MS, Bojsen-Møller KN, Nielsen S, Jørgensen NB, Dirksen C, Kristiansen VB et al. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. Am J Physiol Endocrinol Metab 2016; 310: E505–E514.
    Article Google Scholar
  22. Rehfeld JF . Accurate measurement of cholecystokinin in plasma. Clin Chem 1998; 44: 991–1001.
    CAS PubMed Google Scholar
  23. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ . Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535–539.
    Article CAS Google Scholar
  24. Wewer Albrechtsen NJ, Bak MJ, Hartmann B, Christensen LW, Kuhre RE, Deacon CF et al. Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocr Connect 2015; 4: 50–57.
    Article Google Scholar
  25. Toräng S, Bojsen-Moller KN, Svane MS, Hartmann B, Rosenkilde MM, Madsbad S et al. In vivo and in vitro degradation of peptide YY3–36 to inactive peptide YY3–34 in humans. Am J Physiol Regul Integr Comp Physiol 2016; 310: R866–R874.
    Article Google Scholar
  26. Challis BG, Albrechtsen NJW, Bansiya V, Burling K, Barker P, Hartmann B et al. Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. Endocrinol Diabetes Metab Case Rep 2015; 2015: 150105.
    PubMed PubMed Central Google Scholar
  27. Jørgensen NB, Dirksen C, Bojsen-Møller KN, Kristiansen VB, Wulff BS, Rainteau D et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J Clin Endocrinol Metab 2015; 100: E396–E406.
    Article Google Scholar
  28. Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Jacobsen SH, Clausen TR et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond) 2013; 37: 1452–1459.
    Article CAS Google Scholar
  29. Falkén Y, Hellström PM, Holst JJ, Näslund E . Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 2011; 96: 2227–2235.
    Article Google Scholar
  30. Steinert RE, Schirra J, Meyer-Gerspach AC, Kienle P, Fischer H, Schulte F et al. Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. Am J Clin Nutr 2014; 100: 514–523.
    Article CAS Google Scholar
  31. Melhorn SJ, Tyagi V, Smeraglio A, Roth CL, Schur EA . Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans. Appetite 2014; 82: 85–90.
    Article Google Scholar
  32. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999; 48: 86–93.
    Article CAS Google Scholar
  33. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314: 687–699.
    Article CAS Google Scholar
  34. Medeiros MD, Turner AJ . Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 1994; 134: 2088–2094.
    Article CAS Google Scholar
  35. Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2010; 12: 323–333.
    Article CAS Google Scholar
  36. Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 2013; 304: G1117–G1127.
    Article CAS Google Scholar

Download references